Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction
暂无分享,去创建一个
[1] J. Vacek,et al. Potential use of ubiquinol and d-ribose in patients with heart failure with preserved ejection fraction , 2020, Annals of medicine and surgery.
[2] Y. Huo,et al. Morphometric, Hemodynamic, and Multi-Omics Analyses in Heart Failure Rats with Preserved Ejection Fraction , 2020, International journal of molecular sciences.
[3] F. Giallauria,et al. Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement , 2020, Journal of clinical medicine.
[4] R. Clements,et al. Endurance exercise training in pulmonary hypertension increases skeletal muscle electron transport chain supercomplex assembly , 2020, Pulmonary circulation.
[5] A. Nederveen,et al. TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study , 2020, Netherlands Heart Journal.
[6] Gabriel A. Koepp,et al. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial , 2018, JAMA.
[7] M. Murphy,et al. MitoQ improves mitochondrial dysfunction in heart failure induced by pressure overload , 2018, Free radical biology & medicine.
[8] J. Balschi,et al. Decreased ATP production and myocardial contractile reserve in metabolic heart disease , 2018, Journal of molecular and cellular cardiology.
[9] S. Russell,et al. Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure , 2017, Circulation. Heart failure.
[10] Shannon M. Dunlay,et al. Epidemiology of heart failure with preserved ejection fraction , 2017, Nature Reviews Cardiology.
[11] Sanjiv J. Shah,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study , 2017, European heart journal.
[12] M. Fornage,et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.
[13] Traci L. Marin,et al. AMPK promotes mitochondrial biogenesis and function by phosphorylating the epigenetic factors DNMT1, RBBP7, and HAT1 , 2017, Science Signaling.
[14] S. Raman,et al. Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle. , 2017, Journal of visualized experiments : JoVE.
[15] G. Filippatos,et al. Mitochondrial function as a therapeutic target in heart failure , 2016, Nature Reviews Cardiology.
[16] Marni J. Falk,et al. Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. , 2016, JCI insight.
[17] M. Gheorghiade,et al. Partial Adenosine A1 Agonist in Heart Failure. , 2016, Handbook of experimental pharmacology.
[18] U. Wisløff,et al. Skeletal Muscle Alterations Are Exacerbated in Heart Failure With Reduced Compared With Preserved Ejection Fraction: Mediated by Circulating Cytokines? , 2016, Circulation. Heart failure.
[19] B. Nicklas,et al. Skeletal Muscle Mitochondrial Content, Oxidative Capacity, and Mfn2 Expression Are Reduced in Older Patients With Heart Failure and Preserved Ejection Fraction and Are Related to Exercise Intolerance. , 2016, JACC. Heart failure.
[20] Jacob P. Kelly,et al. Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure , 2016, Journal of the American Heart Association.
[21] V. Melenovský,et al. Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. , 2016, Circulation research.
[22] Yeji Kim,et al. AMPK activators: mechanisms of action and physiological activities , 2016, Experimental & Molecular Medicine.
[23] F. Villarreal,et al. (-)-Epicatechin-induced recovery of mitochondria from simulated diabetes: Potential role of endothelial nitric oxide synthase , 2016, Diabetes & vascular disease research.
[24] Souheila Hachem,et al. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure , 2016, Circulation. Heart failure.
[25] J. Chirinos,et al. The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction , 2016, Current Heart Failure Reports.
[26] V. Melenovský,et al. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. , 2015, Journal of the American College of Cardiology.
[27] J. DiNicolantonio,et al. Coenzyme Q10 for the treatment of heart failure: a review of the literature , 2015, Open Heart.
[28] H. Ranhotra,et al. Estrogen-related receptor alpha and mitochondria: tale of the titans , 2015, Journal of receptor and signal transduction research.
[29] N. Houstis,et al. Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The Role of Abnormal Peripheral Oxygen Extraction , 2015, Circulation. Heart failure.
[30] U. Wisløff,et al. Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle , 2015, European journal of heart failure.
[31] W. Edwards,et al. Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.
[32] R. Townsend,et al. Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.
[33] Rahul C. Deo,et al. Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction , 2015, Circulation.
[34] Ambarish Pandey,et al. Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction: Meta-Analysis of Randomized Control Trials , 2014, Circulation. Heart failure.
[35] Å. Gustafsson,et al. Mitochondrial quality control in the myocardium: cooperation between protein degradation and mitophagy. , 2014, Journal of molecular and cellular cardiology.
[36] R. Sadygov,et al. Cardiac mitochondrial proteome dynamics with heavy water reveals stable rate of mitochondrial protein synthesis in heart failure despite decline in mitochondrial oxidative capacity. , 2014, Journal of molecular and cellular cardiology.
[37] Brian J. Bleakley,et al. Abstract 353: Characterization Of Human Plasma Proteome Dynamics Using Deuterium Oxide , 2014 .
[38] D. Kitzman,et al. Exercise physiology in heart failure and preserved ejection fraction. , 2014, Heart failure clinics.
[39] W. Kraus,et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. , 2014, American journal of physiology. Heart and circulatory physiology.
[40] G. Lopaschuk,et al. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy , 2014, British journal of pharmacology.
[41] Z. Malik,et al. Heart Failure and Mitochondrial Dysfunction: The Role of Mitochondrial Fission/Fusion Abnormalities and New Therapeutic Strategies , 2014, Journal of cardiovascular pharmacology.
[42] Ravinder Reddy,et al. A technique for in vivo mapping of myocardial creatine kinase metabolism , 2014, Nature Medicine.
[43] R. Reddy,et al. Method for high‐resolution imaging of creatine in vivo using chemical exchange saturation transfer , 2014, Magnetic resonance in medicine.
[44] W Michael Southern,et al. A cross-validation of near-infrared spectroscopy measurements of skeletal muscle oxidative capacity with phosphorus magnetic resonance spectroscopy. , 2013, Journal of applied physiology.
[45] S. Solomon,et al. The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction , 2013, Journal of the American Heart Association.
[46] Michael P. Siegel,et al. Mitochondrial‐targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice , 2013, Aging cell.
[47] D. O'Gorman,et al. Time Course Analysis Reveals Gene-Specific Transcript and Protein Kinetics of Adaptation to Short-Term Aerobic Exercise Training in Human Skeletal Muscle , 2013, PloS one.
[48] Stefan Neubauer,et al. Human cardiac 31P magnetic resonance spectroscopy at 7 tesla , 2013, Magnetic resonance in medicine.
[49] G. Lopaschuk,et al. Cardiac Insulin-Resistance and Decreased Mitochondrial Energy Production Precede the Development of Systolic Heart Failure After Pressure-Overload Hypertrophy , 2013, Circulation. Heart failure.
[50] S. Kritchevsky,et al. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.
[51] Ravinder Reddy,et al. Chemical Exchange Saturation Transfer (CEST) Imaging: Description of Technique and Potential Clinical Applications , 2013, Current Radiology Reports.
[52] R. Wachter,et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. , 2013, JACC. Heart failure.
[53] L. Ferrucci,et al. Skeletal muscle mitochondrial energetics are associated with maximal aerobic capacity and walking speed in older adults. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.
[54] Manesh R. Patel,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.
[55] M. Gheorghiade,et al. Mitochondria as a therapeutic target in heart failure. , 2013, Journal of the American College of Cardiology.
[56] Nobel C. Zong,et al. Metabolic Labeling Reveals Proteome Dynamics of Mouse Mitochondria* , 2012, Molecular & Cellular Proteomics.
[57] Kevin K McCully,et al. Noninvasive evaluation of skeletal muscle mitochondrial capacity with near-infrared spectroscopy: correcting for blood volume changes. , 2012, Journal of applied physiology.
[58] D. Kitzman,et al. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. , 2012, Journal of the American College of Cardiology.
[59] R. Boushel,et al. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects , 2012, The Journal of physiology.
[60] Xiao-Ming Yin,et al. Mitophagy: mechanisms, pathophysiological roles, and analysis , 2012, Biological chemistry.
[61] Satoru Takahashi,et al. Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells. , 2012, The British journal of nutrition.
[62] B. Adams-Huet,et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction , 2011, European journal of heart failure.
[63] Ian R. Lanza,et al. Measurement of human skeletal muscle oxidative capacity by 31P‐MR spectroscopy: A cross‐validation with in vitro measurements , 2011, Journal of magnetic resonance imaging : JMRI.
[64] P. Mateo,et al. Resveratrol Improves Survival, Hemodynamics and Energetics in a Rat Model of Hypertension Leading to Heart Failure , 2011, PloS one.
[65] D. Kitzman,et al. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. , 2011, Journal of the American College of Cardiology.
[66] P. Rabinovitch,et al. Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. , 2011, Journal of the American College of Cardiology.
[67] R. D. de Boer,et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. , 2011, American journal of physiology. Heart and circulatory physiology.
[68] D. O'Gorman,et al. 2‐D DIGE analysis of the mitochondrial proteome from human skeletal muscle reveals time course‐dependent remodelling in response to 14 consecutive days of endurance exercise training , 2011, Proteomics.
[69] Melissa M. Thomas,et al. Mitochondrial Structure and Function Are Disrupted by Standard Isolation Methods , 2011, PloS one.
[70] R. Artuch,et al. Combined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia , 2011, The Cerebellum.
[71] K. Sahlin,et al. Dietary inorganic nitrate improves mitochondrial efficiency in humans. , 2011, Cell metabolism.
[72] Z. Bosnjak,et al. SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery. , 2010, Free radical biology & medicine.
[73] S. Guan,et al. Analysis of proteome dynamics in the mouse brain , 2010, Proceedings of the National Academy of Sciences.
[74] Robin A. J. Smith,et al. The mitochondria‐targeted anti‐oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[75] H. Middlekauff. Making the Case for Skeletal Myopathy as the Major Limitation of Exercise Capacity in Heart Failure , 2010, Circulation. Heart failure.
[76] Dachun Yang,et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway , 2010, Journal of cellular and molecular medicine.
[77] Hope D. Anderson,et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. , 2010, American journal of hypertension.
[78] T. Kaneko,et al. Antioxidant, EUK-8, prevents murine dilated cardiomyopathy. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[79] A. Henning,et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. , 2009, Journal of the American College of Cardiology.
[80] S. Jha,et al. Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure , 2009, Circulation research.
[81] J. Sowers,et al. Role of mitochondrial dysfunction in insulin resistance. , 2008, Circulation research.
[82] B. Spiegelman,et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α , 2007, Proceedings of the National Academy of Sciences.
[83] Eric Ravussin,et al. Calorie Restriction Increases Muscle Mitochondrial Biogenesis in Healthy Humans , 2007, PLoS medicine.
[84] D. Kass,et al. Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction , 2006, Circulation.
[85] E. Clementi,et al. Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. , 2005, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[86] Frank J Giordano,et al. Oxygen, oxidative stress, hypoxia, and heart failure. , 2005, The Journal of clinical investigation.
[87] K. Nair,et al. T(3) increases mitochondrial ATP production in oxidative muscle despite increased expression of UCP2 and -3. , 2001, American journal of physiology. Endocrinology and metabolism.
[88] T. Barstow,et al. Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease , 1999, European Journal of Applied Physiology and Occupational Physiology.
[89] K. Nair,et al. Effect of age on in vivo rates of mitochondrial protein synthesis in human skeletal muscle. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[90] H. Drexler,et al. Alterations of Skeletal Muscle in Chronic Heart Failure , 1992, Circulation.
[91] D. Kitzman,et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. , 1991, Journal of the American College of Cardiology.
[92] F. Cobb,et al. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. , 1990, Circulation.
[93] R. Hickson,et al. Separate turnover of cytochrome c and myoglobin in the red types of skeletal muscle. , 1981, The American journal of physiology.
[94] Ewald R. Weibel,et al. The ultrastructure of the normal human skeletal muscle , 1973, Pflügers Archiv.
[95] R. Menzies,et al. The turnover of mitochondria in a variety of tissues of young adult and aged rats. , 1971, The Journal of biological chemistry.
[96] N. Houstis,et al. Exercise Intolerance in Heart Failure With Preserved Ejection Fraction Diagnosing and Ranking Its Causes Using Personalized O 2 Pathway Analysis , 2017 .
[97] P. Ping,et al. Mitochondrial protein turnover: methods to measure turnover rates on a large scale. , 2015, Journal of molecular and cellular cardiology.
[98] R. Sadygov,et al. Mitochondria in Cardiovascular Physiology and Disease Assessment of cardiac proteome dynamics with heavy water : slower protein synthesis rates in interfibrillar than subsarcolemmal mitochondria , 2013 .
[99] T. Doenst,et al. Biphasic response of skeletal muscle mitochondria to chronic cardiac pressure overload - role of respiratory chain complex activity. , 2012, Journal of molecular and cellular cardiology.
[100] B. Sumegi,et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. , 2012, Clinical hemorheology and microcirculation.
[101] S. Neubauer,et al. Magnetic resonance spectroscopy in myocardial disease. , 2009, JACC. Cardiovascular imaging.
[102] Ian R. Lanza,et al. Functional assessment of isolated mitochondria in vitro. , 2009, Methods in enzymology.
[103] G. Dudley,et al. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive heart failure. , 1996, Journal of the American College of Cardiology.
[104] J. Mccormack,et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. , 1996, Circulation.